New chemotherapy treatment could benefit multiple cancer types
European Pharmaceutical Review » Chemotherapy
by
1M ago
The innovative treatment significantly increased survival in patients with malignant pleural mesothelioma, a rare, aggressive cancer, according to Phase III data from UK researchers ..read more
Visit website
CHMP meeting highlights: January 2024
European Pharmaceutical Review » Chemotherapy
by
2M ago
In its first meeting of 2024, the CHMP recommended a generic medicine for schizophrenia and refused a marketing authorisation (MA) for geographic atrophy ..read more
Visit website
Explore how LED microscopy illumination can improve the sustainability of research and development,
European Pharmaceutical Review » Chemotherapy
by
2M ago
..read more
Visit website
Read our latest digital journal for free
European Pharmaceutical Review » Chemotherapy
by
2M ago
..read more
Visit website
Learn how InDevR and their VaxArray multiplexed immunoassay platform empower Critical Quality Attribute (CQA) testing for multivalent mRNA vaccines
European Pharmaceutical Review » Chemotherapy
by
2M ago
..read more
Visit website
Solve your dosage form and delivery challenges with our new webinar
European Pharmaceutical Review » Chemotherapy
by
2M ago
..read more
Visit website
Join this webinar as GMP expert Mark Hallworth discusses the difference between cleanroom classification and monitoring of the new ISO 14644 Technical Report 21.
European Pharmaceutical Review » Chemotherapy
by
2M ago
..read more
Visit website
Hear from industry leaders in our upcoming live sessions
European Pharmaceutical Review » Chemotherapy
by
2M ago
..read more
Visit website
NK cell immunotherapy: what’s next in clinical development?
European Pharmaceutical Review » Chemotherapy
by
4M ago
In this interview, Innate Pharma’s Yannis Morel, Executive Vice President of product portfolio strategy and business development, delves into the unique advantages of using multi-specific antibodies capable of engaging NK cells against tumours for oncology indications, and shares key data from the company’s ongoing and recent clinical trials ..read more
Visit website
Gilead reveals positive data for potential first-line adenocarcinoma treatment
European Pharmaceutical Review » Chemotherapy
by
5M ago
The only Fc-silent anti- T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody in Phase III for upper GI adenocarcinomas could be the first to market for these cancers ..read more
Visit website

Follow European Pharmaceutical Review » Chemotherapy on FeedSpot

Continue with Google
Continue with Apple
OR